[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Catharina Ziekenhuis Eindhoven\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":199},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,75,108,138,170],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100630329","advance-forsee-advanced-video-monitoring-for-early-signaling-of-adverse-events-and-optimal-discharge-planning-100630329",false,"NCT07486258","ADVANCE-FORSEE. ADVANCEd Video Monitoring FOR Early Signaling of Adverse Events and Optimal dischargE Planning.","Inclusion Criteria:\n\n* Patients admitted to the cardiothoracic ward after cardiac surgery\n* Age ≥ 18\n* Willing and able to sign informed consent form\n\nExclusion Criteria:\n\n* Pregnancy\n* Inability to provide written informed consent\n* Mental disability\n* Language barrier","ALL","18 Years",{"count":18,"type":19},250,"ESTIMATED","1 Week","OBSERVATIONAL","In this study cameras placed at the bedside will be evaluated for their ability to safely and accurately measure vital signs, such as heart rate and breathing, continuously after heart surgery. Camera-based measurements will be compared with the usual checks that nurses perform several times a day using sensors on the skin or finger clip.\n\nThe goal is to see whether camera monitoring can help notice changes in a patient's condition earlier. Another aim of the study is to find out whether the camera monitoring can predict if a patient's health is improving or worsening.\n\nPatients and healthcare staff will be asked by the investigators about their experience to learn whether this type of monitoring is acceptable in daily care.",[24,25,26],"Vital Signs Monitoring","Complication","Discharge Planning",[28,24,29,30,31],"ADVANCE FORSEE","Video-based Monitoring","Complication Prediction","Discharge Readiness Planning","NOT_YET_RECRUITING","2026-03-17",{"date":35,"type":36},"2026-03-20","ACTUAL",{"date":38,"type":19},"2026-07",{"date":40,"type":19},"2028-07",{"name":42,"class":43},"Catharina Ziekenhuis Eindhoven","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":44},"100575113","mindfulness-based-intervention-prior-to-external-cephalic-version-100575113","NCT06768060","Mindfulness-based Intervention Prior to External Cephalic Version","Preparing Mothers for External Cephalic Version: a Mindfulness-based Intervention for Pregnant Women With a Baby in Breech Presentation","Inclusion Criteria:\n\n* Pregnant women (18+y).\n* With a breech presenting fetus undergoing external cephalic version.\n* Dutch\u002FEnglish-speaking or understanding Dutch\u002FEnglish.","FEMALE",{"count":54,"type":19},148,"INTERVENTIONAL",[57],"NA","The study is a randomized controlled trial examining the effectiveness of a short mindfulness-based intervention on the success rate of external cephalic version in pregnant women with breech presentation. It is hypothesized that this intervention will increase the ECV success rate and decrease the pain experienced after the ECV.",[60,61],"Breech Presentation in Pregnancy","External Cephalic Version",[63,64,65,66],"Breech presentation","Pregnancy","External cephalic version","Mindfulness intervention","RECRUITING",{"date":69,"type":36},"2026-03-18",{"date":71,"type":36},"2025-02-27",{"date":73,"type":19},"2028-01-31",{"name":42,"class":43},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":15,"minAge":16,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":55,"phases":86,"briefSummary":87,"conditions":88,"keywords":93,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100617093","multivessel-minimally-invasive-coronary-bypass-grafting-as-hybrid-revascularization-versus-conventional-off-pump-coronary-artery-bypass-grafting-100617093","NCT07314138","Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-pump Coronary Artery Bypass Grafting","MICRA-HYBRID Trial: A Randomized Controlled Trial of 'Multivessel Minimally Invasive Coronary Bypass Grafting as HYBRID Revascularization Versus Conventional Off-Pump Coronary Artery Bypass Grafting'","MICRA-HYBRID","Inclusion Criteria:\n\n* Patients with three-vessel disease (either angiographic stenoses \\>70% or a fractional flow reserve value ≤0.80)\n* Left main diameter stenosis ≥50% or a left main intravascular ultrasound minimal luminal area of ≤4.5 mm2 or fractional flow reserve value ≤0.80 combined with significant CAD of the right coronary artery\n\nExclusion Criteria:\n\nA potential participant who meets any of the following criteria will be excluded from participation in this study:\n\n* Age \\\u003C 18 or \\> 85 years\n* Chronic total occlusion of the RCA\n* In-stent RCA restenosis\n* RCA stenosis with high-risk clinical features requiring urgent PCI or surgical revasculari-zation.\n* Reverse hybrid coronary revascularization, defined as PCI-RCA followed by surgical re-vascularization.\n* Acute cardiac ischemia necessitating immediate intervention.\n* EF \\\u003C 30 %\n* eGFR \\\u003C 30 ml\u002Fmin\n* Indication for concomitant cardiac surgery (e.g. valve or arrhythmia surgery) or non-cardiac surgery\n* Previous thoracic or cardiac surgery, mediastinal irradiation, significant trauma to the chest\n* Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure) or cancer.\n* Hemodynamically significant left subclavian stenosis\n* Severe chest wall deformities\n* History of pericarditis\n* Body mass index \\> 40 Kg\u002Fm2.",true,"85 Years",{"count":18,"type":19},[57],"The MICRA-HYBRID trial is a prospective, multicenter, randomized controlled study comparing multivessel hybrid coronary revascularization (HCR) as minimally invasive arterial bypass grafting to left-sided coronary targets (LAD and LCx) plus PCI of the RCA versus conventional off-pump coronary artery bypass grafting (OPCAB) via median sternotomy in patients with three-vessel coronary artery disease. The primary goal is to evaluate whether multivessel-HCR provides superior 30-day \"textbook\" clinical outcomes (mortality, MI, stroke, re-exploration for bleeding, and other complications) while improving perioperative recovery and long-term cardiovascular outcomes.",[89,90,91,92],"Coronary Artery Disease (CAD)","Bypass, Cardiopulmonary","Minimally Invasive Coronary Revascularization Surgery","Off-pump Coronary Artery Bypass",[94,95,96,97,98],"minimally invasive coronary surgery","percutaneous coronary intervention","off-pump coronary artery bypass grafting","hybrid coronary revascularization","heart surgery","2025-12-23",{"date":101,"type":36},"2026-01-02",{"date":103,"type":19},"2026-04-01",{"date":105,"type":19},"2034-05-01",{"name":42,"class":43},2,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":116,"targetDuration":118,"studyType":21,"phases":4,"briefSummary":119,"conditions":120,"keywords":122,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100524165","implementation-of-up-front-ctdna-into-lung-cancer-care-and-development-of-liquid-biopsy-based-decision-support-models---lm-study-100524165","NCT06105177","Implementation of Up-front ctDNA Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - LM² Study","Implementation of Up-front ctDNA Analysis Into Lung Cancer Care and Development of Liquid Biopsy-based Decision Support Models - the Lungmarker² Study","LM2","Inclusion Criteria:\n\n* Aged 18 or above and suspected of having lung cancer\n\nExclusion Criteria:\n\n* Presence of another malignant tumor, i.e. diagnosed with a tumor in the past 5 years",{"count":117,"type":19},800,"36 Months","Despite scientific evidence, use of liquid biopsy (LB) in diagnosis and monitoring of lung cancer (LC) is limited since it requires major changes in diagnostic and care pathways. Analyzing tumor markers (TMs), circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in blood (LB) can inform about the nature of the tumor, the most appropriate therapy, therapy response and resistance.\n\nLungmarker2 is a multicenter, prospective, implementation and diagnostic cohort study. This study aims to implement up-front ctDNA analysis ('plasma first approach') into routine diagnostic work-up of all advanced stage LC patients in the Southeast of the Netherlands (the participating hospitals in the OncoZON region). Thereby, additional information about the molecular make-up of the tumor becomes available, the number of tissue Next-Generation Sequencing (NGS) analyses will decrease and time to therapeutic decision making is shortened. Next, using ctDNA, TM and other information, multi-parametric decision support models are built and validated that may support diagnosis, predict the outcome of the next imaging procedure and progression-free survival during follow-up. The final goal is to develop a super-resolution microscopy test that can detect PD-L1 expression on CTCs.",[121],"Lung Cancer",[123,124,125,126,127,128],"lungmarker2 study","lung cancer","liquid biopsy","ctDNA","CTCs","tumormarkers","2024-09-10",{"date":131,"type":36},"2024-09-19",{"date":133,"type":36},"2023-10-31",{"date":135,"type":19},"2026-10",{"name":42,"class":43},5,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":4,"enrollmentInfo":145,"targetDuration":147,"studyType":21,"phases":4,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100470393","predicting-response-in-cervical-intraepithelial-neoplasia-to-topical-imiquimod-treatment-100470393","NCT05405270","Predicting Response In Cervical Intraepithelial Neoplasia to Topical Imiquimod Treatment","PRedICT-TOPIC","Inclusion Criteria:\n\n* Primary cHSIL lesions (e.g. CIN3 or CIN 2), histologically confirmed by diagnostic biopsy Nota bene: In case of CIN 2, expectative management must be discussed according to the Dutch national guideline with the patient, if the patient prefers imiquimod therapy the patient can be treated with imiquimod and enrolled in the study, if the patient prefers expectative management they can be enrolled in the observational CIN 2 group.\n* Recurrent or residual cHSIL lesions after initial LLETZ treatment (e.g. CIN2 or CIN3), histologically confirmed by diagnostic biopsy\n* Age of 18 years or older\n\nExclusion Criteria:\n\n* Concomitant diagnoses of VAIN (vaginal intraepithelial neoplasia e.g. vaginal HSIL)\n* PAP (Papanicolaou) 4 cytology as indication for the baseline colposcopy at study entrance\n* Adenocarcinoma in situ (AIS) diagnosis\n* Previous imiquimod therapy for cHSIL\n* Previous cervical malignancy\n* Current malignant disease\n* Immunodeficiency (including HIV\u002FAIDS and immunosuppressive medication)\n* Pregnancy\n* Legal incapability\n* Insufficient knowledge of the Dutch language",{"count":146,"type":19},410,"2 Years","Imiquimod is a good non-invasive treatment option for women with cervical high-grade squamous intraepithelial neoplasia (cHSIL), especially those with a possible (future) pregnancy wish. Complete response to imiquimod occurs in 55-73% of patients, however side-effects of imiquimod are common and can be extensive. Therefore, biomarkers which can predict response to imiquimod therapy are warranted, to increase therapy efficacy and to avoid side effects in patients who will not respond.\n\nThis prospective, multi-center cohort study aims to validate the potential of immune related biomarkers to predict the clinical response of patients with primary cHSIL to imiquimod, aims to explore the value of these immune biomarkers in recurrent\u002Fresidual cHSIL to predict treatment responses for imiquimod and aims to explore their potential in spontaneous regression of cHSIL (CIN2).",[150,151,152,153],"Cervical High Grade Squamous Intraepithelial Lesion","Cervical Intraepithelial Neoplasia Grade 2\u002F3","CIN 2\u002F3","Cervical Intraepithelial Neoplasia",[155,156,157,158,159,160],"Cervical high-grade squamous intraepithelial lesion (cHSIL)","Imiquimod","Tumor immunemicroenvironment","High-risk human papilloma virus (hrHPV)","Cervical intraepithelial neoplasia (CIN)","Biomarker","2023-09-08",{"date":163,"type":36},"2023-09-11",{"date":165,"type":36},"2022-06-01",{"date":167,"type":19},"2026-12",{"name":42,"class":43},15,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":55,"phases":180,"briefSummary":182,"conditions":183,"keywords":185,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":198},"100392368","phase-3-induction-chemotherapy-for-locally-recurrent-rectal-cancer-100392368","NCT04389086","Induction Chemotherapy for Locally Recurrent Rectal Cancer","Multicentre, Open-label, Randomised, Controlled, Parallel Arms Clinical Trial of Induction Chemotherapy Followed by Chemoradiotherapy Versus Chemoradiotherapy Alone as Neoadjuvant Treatment for Locally Recurrent Rectal Cancer - PelvEx II","PelvEx II","Inclusion Criteria:\n\n* 18 years or older\n* Confirmed locally recurrent rectal cancer after total or partial mesorectal resection for rectal or distal sigmoidal cancer either by histopathology ór clinically proven (evidence on imaging in combination with clinical findings, with consensus in MDT)\n* Resectable disease determined by magnetic resonance imaging (MRI) or deemed resectable after neoadjuvant treatment with chemoradiotherapy.\n* WHO performance score 0-1\n* Written informed consent\n\nExclusion Criteria:\n\n* Radiological evidence of metastatic disease (e.g. liver, lung) at time of randomisation or in the six months prior to randomisation.\n* Known homozygous DPD deficiency\n* Any chemotherapy in the past 6 months.\n* Any contraindication for the planned chemotherapy, as determined by the medical oncologist.\n* Radiotherapy in the past 6 months for primary rectal cancer.\n* Any contraindication for the planned chemoradiotherapy, as determined by the medical oncologist and\u002For radiation oncologist.\n* Any contraindication for surgery, as determined by the surgeon and\u002For anaesthesiologist.\n* Concurrent malignancies that interfere with the planned study treatment or the prognosis of resected LRRC.",{"count":179,"type":19},364,[181],"PHASE3","This is a multicentre, open-label, parallel arms, phase IIII study that randomises patients with locally recurrent rectal cancer in a 1:1 ratio to receive either induction chemotherapy followed by neoadjuvant chemoradiotherapy and surgery (experimental arm) or neoadjuvant chemoradiotherapy and surgery alone (control arm)",[184],"Recurrent Rectal Cancer",[186,187,188,189],"Locally recurrent rectal cancer","Neoadjuvant therapy","Induction chemotherapy","Resection margin","2022-09-01",{"date":192,"type":36},"2022-09-06",{"date":194,"type":36},"2020-11-13",{"date":196,"type":19},"2030-03-01",{"name":42,"class":43},14,""]